Pharmacylics have closed their first Phase III Ibrutinib trial with 350 patients

Pharmacylics have closed their first Phase III Ibrutinib trial with 350 patients

The Wall Street Journal reports that Pharmacylics today announced that the enrollment target of 350 patients for its Phase III study using ibrutinib monotherapy versus ofatumumab in patients with relapsed or refractory CLL/SLL, has been achieved ahead of schedule and enrollments are now officially closed:

online.wsj.com/article/PR-C...

Good to see patients being thanked too!

It will be interesting to see the outcomes of this larger trial.

Neil

Last edited by

1 Reply

oldestnewest
  • Thanks for the news post Neil, These trials are filling very quickly.

You may also like...